In a study of men with early stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.
The PROCEDE 500 study demonstrated that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.
Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).
A new study found substantial long-term reduction in mortality for men with localized prostate cancer who undergo a radical prostatectomy.
For localized prostate cancer, primary androgen-deprivation therapy does not prolong survival for the majority of men who have not received treatment with curative intent.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|